BioMedNewsBreaks

TuesdayFeb 02, 2021 10:26 am

BioMedNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) to Postpone February Virtual Road Show

Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and healthcare platform, has announced that it will postpone its upcoming virtual road show. Trxade had previously announced that the road show event would be held Wednesday, Feb. 3, 2021, at 11 a.m. ET. The company, which operates across the United States in all 50 states, will reschedule the event and announce the new date and time. Trxade Group is committed to its mission of making healthcare services affordable and accessible. “The virtual roadshow will be postponed to a later date, which will be announced via press release accompanied by a webcast link…

Continue Reading

MondayFeb 01, 2021 3:23 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Issues Shareholder Letter, Corporate Update

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has issued a shareholder letter and corporate update outlining its developments and initiatives for 2020 and anticipated milestones for 2021 and beyond. “We achieved many significant milestones in 2020 that have set the stage for a transformational 2021,” stated Rodney Varner, president and CEO of Genprex. “The primary focus this past year was on the preparation for our two lead clinical trials in non-small cell lung cancer (‘NSCLC’). Our Acclaim-1 clinical trial will combine REQORSA with Tagrisso(R) for patients with late stage NSCLC whose disease progressed…

Continue Reading

MondayFeb 01, 2021 12:30 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Featured in Med-Tech Innovation Article

Brain Scientific (OTCQB: BRSF), a neurology focused device and software company, was featured in a recent Med-Tech Innovation article titled, “The need for neurological disposable tech amid the COVID-19 pandemic.” In the piece, Brain Scientific’s VP of Marketing, Stuart Bernstein, examines the need of neurological disposable technology following the effects of COVID0-19.  “The solution is clear and has come in the form of disposable EEG headsets,” Bernstein writes. “These devices can be quickly integrated into the current, standard medical processes for COVID-19 patients, and those without COVID-19, in need of a brain scan to swiftly acquire, record, transmit and display…

Continue Reading

FridayJan 29, 2021 3:08 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Poised Across Continuum of Health Care

United Medical Equipment (“UME,” “UMEBSNI”) continues to address unique testing needs created by the ongoing global pandemic. As part of the company’s efforts to provide essential services during the epidemic, UMEBSNI is a trusted supplier of FDA-approved COVID-19 rapid antigen test kits that detect coronavirus antibodies that appear in the bloodstream of infected individuals within 10 minutes. The test can also indicate whether a person has protection against the coronavirus. In addition, UMEBSNI offers a unique mobile solution with testing specialists and experienced medical staff members providing onsite COVID-19 Rapid Testing and solutions to implement employee safety. These on-call mobile…

Continue Reading

FridayJan 29, 2021 2:40 pm

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Promising Results from CyberAgrot Study

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an innovative agriculture biotech company focused on providing natural biological protection for high value crops, recently released potentially industry-changing results for its initial Colombia laboratory test. The study evaluated the effect of its proprietary mustard-derived organic biopesticide formulation on the disease Fusarium wilt TR4. MustGrow’s study, conducted and reported via third-party laboratory CyberAgrot SAS in Colombia using Instituto Colombiano Agropecuario (“ICA”) official protocols, reported 100% control of the disease. A recent article discussing this reads, “In the announcement, MustGrow outlined the CyberAgrot study results. Carefully adhering to ICA official protocols, the test evaluated…

Continue Reading

ThursdayJan 28, 2021 2:04 pm

BioMedNewsBreaks – Clearside Biomedical Inc. (NASDAQ: CLSD) Closes Sale of Common Stock for $12M

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that it has closed the sale of 4,209,050 shares of common stock. The shares were priced at $2.851 per share, with the sale resulting in approximately $12 million. In the announcement, Clearside noted that the sale took place with institutional investors and certain existing stockholders. Clearside is recognized for its proprietary SCS Microinjector(R), designed to combat sight-threatening disease. The SCS Microinjector targets the suprachoroidal space (“SCS”) and provides access to the macula,…

Continue Reading

ThursdayJan 28, 2021 1:01 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Featured in BioWorld MedTech Article

Brain Scientific (OTCQB: BRSF), a neurology focused device and software company, was featured in a recent BioWorld MedTech article titled, “Brain Scientific begins development of E-Tattoo device for continuous brain monitoring.” The piece covers Brain Scientific’s efforts to combine a miniaturized electroencephalogram (“EEG”) with subcutaneous graphene electrodes to produce a minimally invasive brain monitoring device that could provide continuous data on patients with neurological conditions. The New York-based company’s device, called the Brain E-Tattoo, would monitor brain wave activity outside the clinical setting and enable long-term continuous data collection without interrupting daily life. To view the full article, visit https://ibn.fm/E85u7…

Continue Reading

ThursdayJan 28, 2021 12:08 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Strategic Contract with Large Pharmaceutical Company

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced a contract between its wholly owned subsidiary, Soluble Biotech Inc., with a large pharmaceutical company. According to the update, the work will involve using Soluble Biotech’s proprietary protein formulation technology to improve the solubility and stability of a protein therapeutic destined for future clinical use. “This opportunity may also lead to a long-term relationship whereby Soluble Biotech develops a strategic partnership to support several other therapeutics currently under development within the pharmaceutical company,” said Dr. Larry DeLucas, founder and…

Continue Reading

ThursdayJan 28, 2021 10:53 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Drug Formulation Strategy, 2021 Milestones

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its drug formulation and delivery business strategy and milestones for 2021. According to the update, XPhyto, as a bioscience accelerator at the leading-edge of the life science industry, targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. Regarding XPhyto's drug formulation business, the company has set the strategy and milestones for 2021 of its wholly owned German subsidiary, Vektor Pharma TF GmbH. Vektor will position itself for commercial manufacturing, pipeline development and drug formulations for critical mental…

Continue Reading

ThursdayJan 28, 2021 10:41 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in First Cohort of MS1819 Study

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, announced that it has completed patient enrollment in the first cohort of its Phase 2b OPTION 2 extension study. The study is evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the announcement, the company noted that the Phase 2b OPTION 2 trial extension arm is dosing patients at sites in the United States and Europe; patients in this study previously participated in arms of the OPTION 2 trial. The ultimate objective of the MS1819 program…

Continue Reading